



Advicenne reports its H1 2025 sales

Paris (France), July 25, 2025 – 7.30 am CEST – Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, reports first half of 2025 sales of €2.6 million, up 9% compared to the first half of 2024. The reported turnover does not include royalties to be received from partners during this period.

Direct sales, booked by Advicenne, rose 17% to €1.27 million. Performance in France was particularly strong with a growth of 48% during the reported period. Overall, sales of Sibnayal® in its European end markets represent €5.18 million, up 90% versus H1 2024.

Turnover (m€)	H1 2025	H1 2024	Growth
Sibnayal®	1,27	1,08	+17%
Neurology	1,36	1,33	+2%
<i>Of which Likoizam®</i>	1,02	0,99	+3%
<i>Of which Levidcen®</i>	0,33	0,34	-3%
Total	2,63	2,42	+9%

At the date of this press release, the Company's cash flow horizon is Q3 2026, thanks to the recent capital increase and the completion of its debt restructuring.

* *
*

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.

For additional information, see: <https://advicenne.com/>.



CONTACTS

Advicenne

Didier Laurens, Directeur Général

+33 (0) 1 87 44 40 17

Email: investors@advicenne.com

Ulysse Communication

Media relations

Bruno Arabian

+33 (0)6 87 88 47 26

Email: advicenne@ulyse-communication.com

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.